Your browser doesn't support javascript.
loading
Targeting IKKß for the treatment of rheumatoid arthritis.
Bamborough, Paul; Morse, Mary A; Ray, Keith P.
Afiliação
  • Bamborough P; GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. paul.a.bamborough@gsk.com
Drug News Perspect ; 23(8): 483-90, 2010 Oct.
Article em En | MEDLINE | ID: mdl-21031164
ABSTRACT
Activation of the nuclear factor-κB (NF-κB) family of transcription factors results in the expression of numerous genes involved in the regulation of the innate and adaptive immune responses, and has been implicated as a key mechanism in chronic inflammatory diseases including rheumatoid arthritis (RA). The IκB kinases (IKKs) are key components in the signaling pathway by which proinflammatory stimuli, such as lipopolysaccharide and tumor necrosis factorlead to the activation of NF-κB. The most widely studied of the IKKs is IKKß. Inhibitors of the kinase activity of IKKß offer opportunities for intervention in RA, as well as other inflammatory disorders. Some examples for which the most extensive data are available will here be reviewed.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Sistemas de Liberação de Medicamentos / Quinase I-kappa B Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Drug News Perspect Assunto da revista: FARMACOLOGIA Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Sistemas de Liberação de Medicamentos / Quinase I-kappa B Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Drug News Perspect Assunto da revista: FARMACOLOGIA Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Reino Unido